PHIO PHARMACEUTICALS CORP
PHIONASDAQTrading Snapshot
- Day Range
- $0.87 – $0.92
- 52-Week Range
- $0.81 – $4.19
- Volume (shares)
- 12,499
- Avg Volume (shares)
- —
- Shares Outstanding
- 11.6M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 74.2x
- EPS (TTM)
- $-1.39
- Dividend Yield
- —
- Dilution (1yr)
- +1375.3%
PHIO PHARMACEUTICALS CORP
PHIO
StockOtter · stockotter.spaceAbout PHIO PHARMACEUTICALS CORP
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Live Presentation and Q&A: Tuesday, October 20, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical co
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing
Phio Pharmaceuticals Highlights 85% Response Rate as PH-762 Nears Phase 2b
Phio Pharmaceuticals (NASDAQ: PHIO) is advancing its lead immuno-oncology candidate, PH-762, as a potential neoadjuvant treatment for cutaneous squamous cell carcinoma, President and Chief Executive Officer Robert Bitter
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.comKing of Prussia, Pennsylvania--(Newsfile
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
Highlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-762 Program in Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. - October 5, 2026) - Phio
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clin